Dementia
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into the global dementia drug market. Track R&D, regulatory approvals, and investment opportunities for Alzheimer's & related diseases.
Showing 1–2 of 2 articles
Quick answer
NovaPharmaNews Dementia hub for FDA covers 2 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
GLP-1 usage statistics show broad uptake and mixed clinical signals
Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.